{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:00:24Z","timestamp":1761512424331},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s11864-006-0032-7","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T18:20:12Z","timestamp":1183573212000},"page":"59-68","source":"Crossref","is-referenced-by-count":18,"title":["Management of small cell lung cancer"],"prefix":"10.1007","volume":"7","author":[{"given":"Kristen Keon","family":"Ciombor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio Max S.","family":"Rocha Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"32_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10\u201330.","journal-title":"CA Cancer J Clin"},{"key":"32_CR2","first-page":"1655","volume-title":"Atlas of Tumor Pathology","author":"JC Ruckdeschel","year":"1994","unstructured":"Ruckdeschel JC, Schwartz AG, Bepler G, et al.: Cancer of the lung: NSCLC and SCLC. In Atlas of Tumor Pathology, edn 3. Edited by Colby TV, Koss MN, Travis WD. Washington, DC: AFIP; 1994:1655.","edition":"edn 3"},{"key":"32_CR3","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","volume":"17","author":"J von Pawel","year":"1999","unstructured":"von Pawel J, Schiller JH, Shepherd FA, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658\u2013667.","journal-title":"J Clin Oncol"},{"key":"32_CR4","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.1990.8.9.1563","volume":"8","author":"KS Albain","year":"1990","unstructured":"Albain KS, Crowley JJ, LeBlanc M, et al.: Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. J Clin Oncol 1990, 8:1563\u20131574.","journal-title":"J Clin Oncol"},{"key":"32_CR5","first-page":"522","volume-title":"Lung Cancer: Principles and Practice","author":"M Kraut","year":"2000","unstructured":"Kraut M, Wozniak A: Clinical presentation. In Lung Cancer: Principles and Practice, edn 2. Edited by Pass HI. Philadelphia: Lippincott Williams &   Wilkins; 2000:522.","edition":"edn 2"},{"key":"32_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.hoc.2003.12.006","volume":"18","author":"M Dusmet","year":"2004","unstructured":"Dusmet M, Goldstraw P: Surgery for small cell lung cancer. Hematol Oncol Clin North Am 2004, 18:323\u2013341.","journal-title":"Hematol Oncol Clin North Am"},{"key":"32_CR7","doi-asserted-by":"publisher","first-page":"259S","DOI":"10.1378\/chest.123.1_suppl.259S","volume":"123","author":"GR Simon","year":"2003","unstructured":"Simon GR, Wagner H: Small cell lung cancer. Chest 2003, 123(Suppl):259S-271S.","journal-title":"Chest"},{"key":"32_CR8","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1378\/chest.119.3.950","volume":"119","author":"HP Hauber","year":"2001","unstructured":"Hauber HP, Bohuslavizki KH, Lund CH, et al.: Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001, 119:950\u2013954.","journal-title":"Chest"},{"key":"32_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s002590100474","volume":"28","author":"T Schumacher","year":"2001","unstructured":"Schumacher T, Brink I, Mix M, et al.: FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001, 28:483\u2013488.","journal-title":"Eur J Nucl Med"},{"key":"32_CR10","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2004.11.089","volume":"22","author":"JD Bradley","year":"2004","unstructured":"Bradley JD, Dehdashti F, Mintun MA, et al.: Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004, 22:3248\u20133254.","journal-title":"J Clin Oncol"},{"issue":"Suppl 9","key":"32_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0093-7754(03)00270-7","volume":"30","author":"R Komaki","year":"2003","unstructured":"Komaki R: Combined treatment for limited small cell lung cancer. Semin Oncol 2003, 30(Suppl 9):56\u201370.","journal-title":"Semin Oncol"},{"key":"32_CR12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1993.11.2.336","volume":"11","author":"N Murray","year":"1993","unstructured":"Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993, 11:336\u2013344.","journal-title":"J Clin Oncol"},{"key":"32_CR13","unstructured":"Goto K, Nishiwaki Y, Takada M, et al.: Final results of a phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) Study [abstract 1805]. http:\/\/www.asco.org. Accessed October 14, 2005."},{"key":"32_CR14","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","volume":"22","author":"DB Fried","year":"2004","unstructured":"Fried DB, Morris DE, Pool C, et al.: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage smallcell lung cancer. J Clin Oncol 2004, 22:4837\u20134845.","journal-title":"J Clin Oncol"},{"key":"32_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM199901283400403","volume":"340","author":"AT Turrisi","year":"1999","unstructured":"Turrisi AT, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265\u2013271.","journal-title":"N Engl J Med"},{"key":"32_CR16","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1200\/JCO.1999.17.9.2681","volume":"17","author":"JA Bonner","year":"1999","unstructured":"Bonner JA, Sloan JA, Shanahan TG, et al.: Phase III comparison of twice-daily split-course irradiation versus oncedaily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999, 17:2681\u20132691.","journal-title":"J Clin Oncol"},{"key":"32_CR17","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","volume":"20","author":"M Takada","year":"2002","unstructured":"Takada M, Fukuoka M, Kawahara M, et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002, 20:3054\u20133060.","journal-title":"J Clin Oncol"},{"key":"32_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJM199908123410703","volume":"341","author":"A Auperin","year":"1999","unstructured":"Auperin A, Arriagada R, Pignon JP, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Irradiation Overview Collaborative Group. N Engl J Med 1999, 341:476\u2013484.","journal-title":"N Engl J Med"},{"key":"32_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jnci\/87.3.183","volume":"87","author":"R Arriagada","year":"2004","unstructured":"Arriagada R, Le Chevalier T, Borie F, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 2004, 87:183\u2013190.","journal-title":"J Natl Cancer Inst"},{"key":"32_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0169-5002(00)00127-6","volume":"30","author":"C Mascaux","year":"2000","unstructured":"Mascaux C, Paesmans M, Berghman T, et al.: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small-cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000, 30:23\u201336.","journal-title":"Lung Cancer"},{"key":"32_CR21","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","volume":"20","author":"S Sundstrom","year":"2002","unstructured":"Sundstrom S, Bremnes RM, Kaasa S, et al.: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20:4665\u20134672.","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"32_CR22","first-page":"23","volume":"21","author":"PA Kosmidis","year":"1994","unstructured":"Kosmidis PA, Samantas E, Fountzilas G, et al.: Cisplatin\/etoposide versus carboplatin\/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994, 21(Suppl 6):23\u201330.","journal-title":"Semin Oncol"},{"key":"32_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85\u201391.","journal-title":"N Engl J Med"},{"key":"32_CR24","doi-asserted-by":"crossref","unstructured":"Hanna NH, Einhorn L, Sandler A, et al.: Randomized, phase III trial comparing irinotecan\/cisplatin (IP) with etoposide\/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC) [abstract LBA 7004]. http:\/\/www.asco.org. Accessed October 14, 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.lba7004"},{"key":"32_CR25","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.1995.13.10.2594","volume":"13","author":"PJ Sr Loehrer","year":"1995","unstructured":"Loehrer PJ Sr, Ansari R, Gonin R, et al.: Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995, 13:2594\u20132599.","journal-title":"J Clin Oncol"},{"key":"32_CR26","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","volume":"23","author":"HB Niell","year":"2005","unstructured":"Niell HB, Herndon JE, Miller AA, et al.: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colonystimulating factor in patients with extensive stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005, 23:3752\u20133759.","journal-title":"J Clin Oncol"},{"key":"32_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/00001622-200403000-00009","volume":"16","author":"K Chrystal","year":"2004","unstructured":"Chrystal K, Cheong K, Harper P: Chemotherapy of small cell lung cancer: state of the art. Curr Opin Oncol 2004, 16:136\u2013140.","journal-title":"Curr Opin Oncol"},{"key":"32_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/sonc.2003.50012","volume":"30","author":"AB Sandler","year":"2003","unstructured":"Sandler AB: Chemotherapy for small cell lung cancer. Semin Oncol 2003, 30:9\u201325. This review is comprehensive in its scope of chemotherapeutic agents and administration strategies in limited-stage and extensive-stage SCLC.","journal-title":"Semin Oncol"},{"key":"32_CR29","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.2002.02.069","volume":"20","author":"A Ardizzoni","year":"2002","unstructured":"Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, et al.: Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002, 20:3947\u20133955.","journal-title":"J Clin Oncol"},{"key":"32_CR30","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/jnci\/dji114","volume":"97","author":"P Lorigan","year":"2005","unstructured":"Lorigan P, Woll PJ, O'Brien MER, et al.: Randomized phase III trial of dose-dense chemotherapy supported by wholeblood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005, 97:666\u2013674.","journal-title":"J Natl Cancer Inst"},{"key":"32_CR31","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/annonc\/mdf249","volume":"13","author":"VC Tjan-Heijnen","year":"2002","unstructured":"Tjan-Heijnen VC, Wagener DJ, Postmus PE: An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 2002, 13:1519\u20131530.","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"32_CR32","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0169-5002(03)90519-8","volume":"41","author":"J von Pawel","year":"2003","unstructured":"von Pawel J: The role of topotecan in treating small cell lung cancer: second-line treatment. Lung Cancer 2003, 41(Suppl 4):S3-S8.","journal-title":"Lung Cancer"},{"key":"32_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jjco\/27.3.166","volume":"27","author":"NKK Ebi","year":"1997","unstructured":"Ebi NKK, Nishiwaki Y, Hojo F, et al.: Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997, 27:166\u2013171.","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 1","key":"32_CR34","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/S0169-5002(01)00309-9","volume":"33","author":"W Schuette","year":"2001","unstructured":"Schuette W: Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer 2001, 33(Suppl 1):S99-S107.","journal-title":"Lung Cancer"},{"key":"32_CR35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.2001.19.6.1743","volume":"19","author":"J von Pawel","year":"2001","unstructured":"von Pawel J, Gatzemeier U, Pujol JL, et al.: Phase II comparator study of oral and intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001, 19:1743\u20131749.","journal-title":"J Clin Oncol"},{"key":"32_CR36","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1200\/JCO.2003.09.130","volume":"21","author":"GA Masters","year":"2003","unstructured":"Masters GA, Declerck L, Blanke C, et al.: Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003, 21:1550\u20131555.","journal-title":"J Clin Oncol"},{"key":"32_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1023\/A:1011104509759","volume":"12","author":"I Van der Lee","year":"2001","unstructured":"Van der Lee I, Smit EF, van Putten JW, et al.: Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 2001, 12:557\u2013561.","journal-title":"Ann Oncol"},{"key":"32_CR38","unstructured":"Nakamura H, Azuma M, Miyagi K, et al.: A pilot study of docetaxel (TXT) as salvage chemotherapy in small cell lung cancer (SCLC) [abstract 2872]. http:\/\/www.asco.org. Accessed October 14, 2005."},{"key":"32_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000227555","volume":"53","author":"K Furuse","year":"1996","unstructured":"Furuse K, Kubota K, Kawahara M, et al.: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996, 53:169\u2013172.","journal-title":"Oncology"},{"key":"32_CR40","first-page":"473a","volume":"16","author":"D Lake","year":"1997","unstructured":"Lake D, Johnson E, Herndon J, et al.: Phase II trial of navelbine (NVB) in relapsed small cell lung cancer (SCLC) [abstract 1703]. Proc Am Soc Clin Oncol 1997, 16:473a.","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"32_CR41","first-page":"11","volume":"15","author":"AB Sandler","year":"2001","unstructured":"Sandler AB: Irinotecan in small-cell lung cancer: the US experience. Oncology (Williston Park) 2001, 15(Suppl 1):11\u201312.","journal-title":"Oncology (Williston Park)"},{"key":"32_CR42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/bjc.1998.54","volume":"77","author":"EF Smit","year":"1998","unstructured":"Smit EF, Fokkema E, Biesma B, et al.: A phase II study of paclitaxel in heavily pretreated patients with smallcell lung cancer. Br J Cancer 1998, 77:347\u2013351.","journal-title":"Br J Cancer"},{"key":"32_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.hoc.2004.01.001","volume":"18","author":"H Wakelee","year":"2004","unstructured":"Wakelee H, Kelly K: Novel approaches for the treatment of small cell lung cancer. Hematol Oncol Clin North Am 2004, 18:499\u2013518. This is an excellent review of recent developments and strategies for targeted therapies for SCLC.","journal-title":"Hematol Oncol Clin North Am"},{"key":"32_CR44","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1200\/JCO.2002.02.108","volume":"20","author":"FA Shepherd","year":"2002","unstructured":"Shepherd FA, Giaccone G, Seymour L, et al.: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002, 20:4434\u20134439.","journal-title":"J Clin Oncol"},{"key":"32_CR45","doi-asserted-by":"crossref","unstructured":"Pandya KJ, Levy DE, Hidalgo M, et al.: A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small lung cancer in remission after induction chemotherapy: a preliminary report [abstract 7005]. http:\/\/www.asco.org. Accessed October 14, 2005.","DOI":"10.1016\/S0169-5002(05)80292-2"},{"key":"32_CR46","doi-asserted-by":"crossref","unstructured":"Johl J, Chansky K, Lara PN, et al.: The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (ESCLC): a SWOG (0327) phase II trial [abstract 7047]. http:\/\/www.asco.org. Accessed October 14, 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.7047"},{"key":"32_CR47","first-page":"188","volume":"9","author":"BE Johnson","year":"2003","unstructured":"Johnson BE, Fisher T, Fisher B, et al.: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003, 9:188\u2013194.","journal-title":"Clin Cancer Res"},{"key":"32_CR48","doi-asserted-by":"crossref","unstructured":"Thompson DS, Hainsworth JD, Spigel DR, et al.: Irinotecan (I), carboplatin (C), and imatinib (IM) in the first-line treatment of extensive-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network [abstract 7049]. http:\/\/www.asco.org. Accessed October 14, 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.7049"},{"key":"32_CR49","doi-asserted-by":"crossref","unstructured":"Fossella F, McCann J, Tolcher A, et al.: Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma [abstract 7159]. http:\/\/www.asco.org. Accessed October 14, 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.7159"},{"key":"32_CR50","doi-asserted-by":"crossref","unstructured":"Cooney MM, Subbiah S, Chapman R, et al.: Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission [abstract 7166]. http:\/\/www.asco.org. Accessed October 14, 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.7166"},{"key":"32_CR51","doi-asserted-by":"crossref","unstructured":"Raefsky EL, Spigel DR, Greco FA, et al.: Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network [abstract 7050]. http:\/\/www.asco.org. Accessed October 14, 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.7050"},{"key":"32_CR52","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/annonc\/mdh315","volume":"15","author":"JV Heymach","year":"2004","unstructured":"Heymach JV, Johnson DH, Khuri FR, et al.: Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004, 15:1187\u20131193.","journal-title":"Ann Oncol"},{"key":"32_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/annonc\/mdf124","volume":"13","author":"CM Rudin","year":"2002","unstructured":"Rudin CM, Otterson GA, Mauer AM, et al.: A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002, 13:539\u2013545.","journal-title":"Ann Oncol"},{"key":"32_CR54","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.2004.10.148","volume":"22","author":"C Rudin","year":"2004","unstructured":"Rudin C, Kozloff M, Hoffman PC, et al.: Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004, 22:1110\u20131117.","journal-title":"J Clin Oncol"},{"key":"32_CR55","first-page":"1319","volume":"5","author":"SC Grant","year":"1999","unstructured":"Grant SC, Kris MG, Houghton AN, et al.: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999, 5:1319\u20131323.","journal-title":"Clin Cancer Res"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-006-0032-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0032-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T14:17:35Z","timestamp":1652624255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-006-0032-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s11864-006-0032-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}